Invivyd, Inc. (NASDAQ:IVVD) Short Interest Update

Invivyd, Inc. (NASDAQ:IVVD) experienced a significant increase in short interest during February 2023. As of February 15th, short interest was reported at 8,510,000 shares, representing a rise of 28.5% from the January 31st figure of 6,620,000 shares. This surge indicates that currently, 11.2% of the company's shares are short sold. The average daily trading volume stands at 13,950,000 shares, resulting in a days-to-cover ratio of 0.6 days.

Invivyd Stock Performance

In trading on Tuesday, Invivyd's shares rose by 11.7%, adding $0.11 to reach $1.05. The trading volume for the day was 10,577,105 shares, compared to an average volume of 21,932,908. Over the past year, Invivyd's stock has fluctuated from a low of $0.35 to a high of $4.74. Currently, the company has a 50-day simple moving average of $0.89 and a 200-day simple moving average of $0.87. Its market capitalization is $125.60 million, with a price-to-earnings ratio of -0.54 and a beta of 0.61.

Analysts’ Price Predictions

Multiple brokerages have updated their price targets for Invivyd. Morgan Stanley reduced its price target from $9.50 to $3.55 while maintaining an "overweight" rating. D. Boral Capital reaffirmed a "buy" rating with a target price of $9.00. Meanwhile, HC Wainwright also restated a "buy" rating with a $10.00 target price. Presently, four analysts have a positive buy rating on the stock while one has issued a strong buy rating. According to MarketBeat, Invivyd has an average rating of "Buy" and a consensus price target of $7.89.

Insider Activity

Recent insider transactions include Director Terrance Mcguire selling 65,359 shares of Invivyd's stock on December 16th. These shares were sold at an average price of $0.47, totaling $30,718.73. After this transaction, Mcguire holds 4,012,320 shares valued at approximately $1,885,790.40, marking a 1.60% decrease in his ownership. In the past quarter, company insiders have sold a total of 816,466 shares worth $423,214, and insiders currently own 17.90% of the stock.

Institutional Investment in Invivyd

Several large institutional investors have recently adjusted their stakes in Invivyd. Two Sigma Investments LP increased its holdings by 125.3% in the fourth quarter, now owning 367,100 shares valued at $163,000 after acquiring an additional 204,188 shares. Similarly, Two Sigma Advisers LP boosted its position by a remarkable 1,276.5%, owning 304,200 shares valued at $135,000. Mithril II GP LP established a new position worth $4,981,000 in Invivyd. Deutsche Bank AG raised its stake by 35.2%, now holding 874,406 shares valued at $385,000 after purchasing an additional 227,463 shares. Jane Street Group LLC also boosted its stake by 290.5%, bringing its total to 117,432 shares valued at $52,000. Institutional investors hold 70.36% of the stock in total.

About Invivyd, Inc.

Invivyd, Inc. is a commercial-stage biopharmaceutical company focused on developing antibody-based solutions for infectious diseases in the United States. One of its key developments is the INVYMAB platform, which integrates viral surveillance and predictive modeling with advanced antibody engineering.

Investment Considerations

Before considering an investment in Invivyd, it's important to analyze the current market dynamics and enlist the advice of top-rated analysts. Recent insights suggest that while Invivyd maintains a Buy rating, several analysts have identified other stocks as potentially better investment opportunities.

Invivyd, Stocks, ShortInterest